Elicio Therapeutics Company
Elicio Therapeutics develops an immuno-tumor vaccine to treat cancer.
Technology:
DNA, Peptides and Proteins, RNA
Industry:
DNA, Peptides and Proteins, RNA
Headquarters:
Cambridge, Massachusetts, United States
Founded Date:
2011-01-01
Employees Number:
11-50
Funding Status:
Early Stage Venture
Investors Number:
6
Total Funding:
120000000
Estimated Revenue:
$1M to $10M
Last Funding Date:
2022-05-27
Last Funding Type:
Seed
Register and Claim Ownership